Italia markets close in 1 hour 2 minutes
FTSE MIB
35.344,39 -65,74 (-0,19%) Dow Jones
39.898,86 +29,48 (+0,07%) Nasdaq
16.712,34 +14,02 (+0,08%) Nikkei 225
38.787,38 -132,88 (-0,34%) Petrolio
79,39 +0,16 (+0,20%) Bitcoin EUR
61.120,07 +437,85 (+0,72%)
NBIX May 2024 155.000 put
OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
In data: 03:24PM EDT. Mercato aperto.
| Chiusura precedente | 23,03 |
| Aperto | N/D |
| Denaro | 11,20 |
| Lettera | 15,50 |
| Prezzo d'esercizio | 155,00 |
| Scadenza | 2024-05-17 |
| Min-Max giorno | 23,03 - 23,03 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | N/D |
GlobeNewswireSosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat
© 2024 Yahoo. Tutti i diritti riservati.